Cytokinetics Inc (CYTK) Actualités

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Cytokinetics to Participate in the 2024 Jefferies London Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK...

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-4015089

Advancement of Fast Skeletal Muscle Troponin Activator Expands Pipeline of Muscle-Directed Drug Candidates...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Cytokinetics Reports Third Quarter 2024 Financial Results

Rolling Submission of NDA for Aficamten Completed and Submitted to FDA in Q3 COMET-HF, Confirmatory Phase 3...

Cytokinetics Announces Six Upcoming Presentations at the American Heart Association Scientific Sessions 2024

SOUTH SAN FRANCISCO, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK...

Form 4 - Statement of changes in beneficial ownership of securities

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK...

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities